Halaman 9

4.8 (95% CI: 0.27-83.3) and hyperuricemia after chemotherapy has p = 0.391 (p> 0.05) and OR =
3.06 (IK95%: 0.24-37.8) against GnGA.
.
The results of this study can contribute GnGA data on risks that can occur in patients with LLA-
L1 chemotherapy induction phase so that it can be done the first week of early prevention. And
the results of this study indicate that the LLA-L1 protocol 2006, Indonesia can lower uric acid
levels were significantly better in the SR and HR as well as minimize the risk GnGA visible from
decreased levels of serum creatinine and GFR improvement after chemotherapy. Given that the
elimination of uric acid as a key GnGA handling and SLT, the essential hydration applied to
patients first diagnosed with LLA-L1 or before undergoing chemotherapy to ensure clearance of
uric acid to prevent uric acid precipitation

CONCLUSION AND RECOMMENDATION

Based on the results of the study concluded that the levels of uric acid and serum creatinine was
higher in the high risk group compared to the standard risk LLA-L1. Levels of serum uric acid and
creatinine decreased after chemotherapy either at standard risk and high risk. The frequency of
hyperuricemia of all samples LLA-L1 before chemotherapy was 21.6% (13/60) and after
chemotherapy hyperuricemia frequency decreased to 15% (9/60). Frequency GnGA before
chemotherapy 3.3% (2/60) and after chemotherapy to 5% (3/60). And GnGA only found on high-
risk groups. Hydration is important to do before chemotherapy to prevent tumor lysis syndrome
even GnGA. LLA-L1 protocol 2006, Indonesia and the procedures for reducing levels of uric acid
and serum creatinine in the first week induction phase. Researchers suggested that conducted a
prospective cohort study in a teaching hospital in Indonesia with large sample. The next study is
expected to measure levels of phosphate, calcium and electrolytes so as to assess a tumor lysis
syndrome.